Cuprina announced that its indirect 49%-owned associate, Cuprina MENA had completed the set-up of a laboratory, located in Saudi Arabia, equipped to manufacture the company’s MEDIFLY maggot debridement therapy for the treatment of chronic wounds and to supply the therapy across the Middle East and North Africa, MENA, region. Cuprina MENA is now working towards obtaining the regulatory approvals, including the Saudi Food and Drug Authority license and ISO 13485 certification, required in order to sell the therapy in the MENA region. In another development, Cuprina MENA has secured exclusive rights from Biopharm UK to sell these leeches across the Gulf Cooperation Council countries.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CUPR:
- Cuprina Holdings Completes Over-Allotment Option, Raising $1.8 Million
- Cuprina Holdings Announces Shareholder Structure as of May 8, 2025
- Cuprina Holdings Completes IVF Media Facility in Singapore
- Cuprina Holdings obtains dealer license for IVF media production facility
- Opening Day: Smart Digital, Yuanbao make debuts